Navigation Links
Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
Date:6/8/2008

For each subject, the trial is expected to take 14.5 months: 2.5 months for screening and subject treatment and a further 12 months for subject follow-up. Individuals interested in participating in this trial should visit http://www.clinicaltrials.gov/ .

About Diabetic Neuropathy

Diabetic peripheral neuropathy is one of the most frequent complications of diabetes. Symptoms include numbness, tingling sensations and pain particularly in the toes or feet. This gradually evolves to loss of sensation and motor function as nerve damage progresses. Ulcers and sores may appear on numb areas of the foot because pressure or injury goes unnoticed. Despite adequate treatment, these areas of trauma frequently become infected and this infection may spread to the bone, necessitating amputation of the leg or foot. More than 60 percent of non-traumatic lower-limb amputations in the United States occur among people with diabetes. In the period from 2000 to 2001, this translated to approximately 82,000 amputations. The American Diabetes Association estimates that there are approximately 20.8 million people with diabetes in the United States and that of those about 60 percent to 70 percent have mild to severe forms of neuropathy. According to the Centers for Disease Control, diabetes is becoming more common in the United States. From 1980 through 2002, the number of Americans with diabetes more than doubled.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused o
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
2. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
3. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
4. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
5. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
6. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
7. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
8. Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743
9. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
10. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
11. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013  Net Medical Xpress Solutions, Inc., (OTC ... today the company has signed a letter of intent ... in Huntsville, AL . MedTel Solutions ... staffing and recruitment of telemedicine physicians. Consideration for the ... agreement, which is expected by June 30, 2013. ...
(Date:5/23/2013)... -- Israel Brain Technologies (IBT) has announced the ... 1 st International Brain Technology Conference, which ... in Tel Aviv , recently ranked as ... by the Wall Street Journal and the epicenter ... showcase the latest breakthroughs in neuroscience and brain technology and ...
(Date:5/23/2013)... 2013  Datameer announced today that Cardinal Health ... on their big data platform. Datameer gives Cardinal ... to quickly and easily visualize and understand data ... 19 company, Cardinal Health is one of the ... and medical products to more than 60,000 locations ...
Breaking Medicine Technology:Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 2Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 3Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 2Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 3Cardinal Health Selects Datameer for Healthcare Data Discovery 2
... SNY ) announced today that it has submitted ... ) in an all-cash transaction valued at approximately $18.5 billion. ... Genzyme shareholders would receive $69 per Genzyme share in cash, ... $49.86 on July 1, 2010. Sanofi-aventis, offer also represents a ...
... Inc. Magazine/Inc.com selects online retail company PainReliever.com (Pain Relievers, ... in the United States. PainReliever.com is owned by Norris ... that a store from Norris E-Commerce Management has won ... was awarded as an Inc. 5000 recipient. ...
Cached Medicine Technology:Sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme 2Sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme 3Sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme 4Sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme 5Sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme 6Sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme 7Sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme 8PainReliever.com Earns Inc. 5000 Award 2
(Date:5/23/2013)... Ill. (May 23, 2013) Aortic arch pulse wave ... independent predictor of disease of the vessels that supply ... published in the June issue the journal Radiology ... arch provides functional information about vessel compliance that may ... the road," said Kevin S. King, M.D., assistant professor ...
(Date:5/23/2013)... Elegance for a woman takes on so many different styles. ... can often be found in the mystery of her eyes. It ... through her eyes. It is also true that that her ... the elegance of a woman can be found in her precise ... any other time, utilize eyewear to not only compliment but to ...
(Date:5/23/2013)... Los Angeles, CA (PRWEB) May 23, 2013 ... showcasing the most innovative and stylish eco-friendly hybrids and electric ... savored than in Los Angeles, the symbolic green car capital. ... annual Green Car Tour ride and drive back to ... modern design event. , During the first two days ...
(Date:5/23/2013)... neuroblastoma a common tumor that forms in the nerve ... A study published by Cell Press in the May ... a new genomic approach to screen for compounds that ... differentiate, or convert from immature cells to more specialized ... a compound that causes neuroblastoma cells to differentiate, uncovering ...
(Date:5/23/2013)... Diabetes is one of the worst diseases ... when patients are unfortunate enough to become victims of ... Information Clearinghouse at http://goo.gl/QyhCz , about 60-70 percent ... neuropathy which further shrivels the nervous system and causes ... nerve damage affects the whole body instead of just ...
Breaking Medicine News(10 mins):Health News:MRI-based measurement helps predict vascular disease in the brain 2Health News:Dolabany Eyewear Adds Feminine Flare to Women's Designer Eyewear with 2013 New Release of Adelina by Best Image Optical, Inc. 2Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 2Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 3Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 4Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 5Health News:New screening approach uncovers potential alternative drug therapies for neuroblastoma 2Health News:Neuropathy Nerve Damage Can Now Be Reversed With Neuracel 2
... April 2009, the US District Court for the District ... restraining order, barring Apotex (Apotex, Inc. and Apotex Corp.) ... until further order of the court. On 27 ... determine whether the injunction should be continued.On 30 March ...
... the highlights of the annual meeting of the American ... TV quiz shows. , Like a quiz show, Neurobowl ... subtracts points for wrong answers. The tougher the question, ... to diagnose perplexing neurological conditions, based on symptoms, video ...
... ANDOVER, Mass., April 16 JAZD Markets, the leader in ... announced that it has recently added SEO/SEM veteran Eric Melin ... team to optimize the directory verticals and report directly to ... SEO Guru in Eric Melin , JAZD is ...
... many people out of work, each day, thousands of new ... to this, FDP Inc. has assembled a directory website to ... With average waiting times of one to three years ... and take any job they can find. But, with fewer ...
... Calif., April 16 The California Dental ... deadline is rapidly approaching to have your kindergartener receive ... 2009-10 school year.The requirement has been in effect for ... common chronic childhood disease, it is essential that children ...
... MedInsights, Inc. , a leading provider of ... VIIAD,s award-winning Health Ticket technology ... to adopt VIIAD,s Health Ticket.The MedInsights Care Ticket, powered ... that goes beyond a traditional group health card and ...
Cached Medicine News:Health News:Court Grants AstraZeneca Temporary Restraining Order Against Apotex in PULMICORT RESPULES Patent Litigation 2Health News:What do neurologists do for entertainment? 2Health News:JAZD Adds Search Marketing & SEO Executive Eric Melin as VP, Traffic Generation Team 2Health News:Social Security Attorney Directory Helps to Speed SSDI Benefits 2Health News:California Dental Association Reminds Parents of Kindergarten Dental Check-Up Requirement 2Health News:National Managed Care Provider First to Workers' Compensation Market with Innovative Technology that Reduces Costs to Employers 2
... ( RIFA:) test for the ... serum IgM antibodies to Epstein-Barr ... kit contains ten 12-well slides ... antigen, FITC IgM RIFA: conjugate, ...
... battery-powered, micro-controlled, noninvasive bone growth stimulator indicated ... lumbar spinal fusion surgery for one or ... shown in pre-clinical studies to help the ... studies have also shown that individuals who ...
... adjunctive treatment alternative in the treatment of ... the appendicular system. , Overview , ... leading provider of bone growth stimulators , ... or adjunct to surgery , Indicated for ...
... surgically implanted bone growth stimulator for the ... surgically implanted bone growth stimulator is a ... when surgery is already planned or when ... the OsteoGen is totally surgically implanted, patients ...
Medicine Products: